BrainChild Bio CEO Steven Brugger (L) and CSO Mike Jensen

A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

In 2021, the FDA ap­proved Bris­tol My­ers Squibb’s Breyanzi for some adult lym­phoma pa­tients, mak­ing it the third CAR-T ther­a­py to be­come com­mer­cial­ly avail­able.

The treat­ment was in­vent­ed at Seat­tle Chil­dren’s Hos­pi­tal, and the first clin­i­cal study was in pe­di­atric pa­tients. Mike Jensen, chief ther­a­peu­tics of­fi­cer at Seat­tle Chil­dren’s and the physi­cian-sci­en­tist be­hind Breyanzi, hoped that Bris­tol My­ers would seek ap­proval for chil­dren next.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.